Post-marketing Observational Clinical Study: Assessment of the Effectiveness (Efficacy) of Odeston (Odeston®) in Patients With Chronic Cholecystitis in Real Medical Practice

Inclusion Criteria:

• Men and women aged 18 to 65 years;
• BMI 18.5 - 40;
• Verified diagnosis: chronic acalculous cholecystitis;
• Voluntary desire to provide informed consent to participate in the study

Exclusion Criteria:

• Presence of stones in the gall bladder and bile ducts;
• The presence of jaundice, cholestatic liver diseases, liver cirrhosis with decompensation;
• Increased ALT, AST above the 3 upper limits of normal;
• Hypersensitivity to the components of the drug Odeston;
• Pregnancy and lactation;
• Prolonged fasting and total parenteral nutrition;
• Patients with symptoms of acute abdomen at the time of inclusion in the study;
• Patients with symptoms of acute neurological pathology at the time of inclusion in the study and/or аcute cerebrovascular accident, a history of convulsive syndrome;
• Presence of cancer;
• Acute infectious diseases at the time of inclusion in the study;
• Fever of any origin (above 37.5 C);
• Patients with symptoms of heart failure;
• Patients with symptoms of pulmonary failure;
• Patients with symptoms of acute or chronic renal failure;
• A decompensated form of diabetes;
• Patients with signs of psychiatric disorders.

Patients of both sexes aged ≥18 to 65 years inclusive with a verified diagnosis: chronic acalculous cholecystitis